How Much Does a GLP-1 Cost Without Insurance?

Most people shopping for a GLP-1 discover the same uncomfortable fact: their insurance does not cover weight-loss medication, or covers it only with prior authorizations they cannot clear. That leaves cash-pay — and the good news is that the cash-pay landscape in 2026 is nothing like the $1,000-plus retail sticker that scared everyone off two years ago. There are now three distinct ways to buy a GLP-1 without insurance, and they differ by hundreds of dollars a month. Here is what each really costs, and how to pay the least for the result you actually want.

Why "without insurance" is the normal case, not the exception

Weight-loss coverage is patchy. Many commercial plans exclude anti-obesity medication outright, Medicare's coverage of these drugs for weight loss is limited, and even covered patients often face step therapy or prior authorization. So a large share of GLP-1 users are, functionally, cash-pay. That is not a fringe situation to work around — it is the situation to plan for. The whole premise of our [value leaderboard](/#leaderboard) is ranking providers on what a self-pay patient truly spends over a year, not on an insurance-adjusted fantasy price.

Route 1: manufacturer self-pay (brand, FDA-approved)

The biggest change is that both major manufacturers now sell their branded drugs directly to cash patients, well below the old pharmacy list price. For Wegovy (semaglutide), Novo Nordisk's self-pay channel prices the medication at around $499 per month for patients paying out of pocket. For Zepbound (tirzepatide), Eli Lilly sells single-dose vials directly at roughly $349 to $499 per month depending on the dose, with the lower starter doses cheaper and higher maintenance doses near the top of that band (per each manufacturer's published self-pay pricing, last reviewed 2026; these programs change their terms and prices frequently). Both routes are the genuine FDA-approved product — the same molecule studied in the pivotal trials, where semaglutide 2.4 mg produced roughly 15% mean weight loss¹ and tirzepatide up to about 21% at its highest dose². The trade-off: brand self-pay is the most expensive of the three routes, and the vial formats can require a bit more handling than the autoinjector pens. Our brand-versus-compounded cost breakdown walks the full comparison.

Route 2: compounded GLP-1 via telehealth

Compounded semaglutide and tirzepatide, dispensed through telehealth providers, have been the cheapest route — with disclosed prices reaching as low as roughly $65 to $200 per month for compounded semaglutide and often $150 to $349 for compounded tirzepatide (per each provider's published pricing, last reviewed 2026). The important caveat is regulatory: after the FDA declared the semaglutide and tirzepatide shortages resolved, the broad legal basis for mass-compounding these molecules narrowed, and the compounded market has been shifting accordingly. Compounded products are also not FDA-approved and not reviewed for safety, efficacy, or quality the way the brand is. That does not make every compounded program a bad choice, but it does make provider vetting non-negotiable — start with is compounded semaglutide legit and safe before you buy on price alone, and use the full monthly cost guide for current numbers.

Route 3: telehealth memberships (watch the teaser)

Many telehealth brands wrap the medication in a membership — a monthly fee that bundles the prescription, clinician access, and coaching. The advertised entry price is frequently a teaser that steps up after month one, and the bundle can hide consult fees, lab charges, and coaching subscriptions you cannot cancel independently. The sticker is not the budget. Before you commit, run every finalist through the true monthly cost of GLP-1 and price the whole year, not the hook. The cost calculators do that arithmetic, and the compare tool lines finalists up on the honest number.

The number that changes everything: this is an annual purchase

Here is the value insight that reframes the entire "without insurance" question. A GLP-1 is not a one-time buy — the benefit depends on staying on it. When treatment is stopped, the weight tends to come back: in the semaglutide withdrawal trial, people who switched to placebo regained a substantial share of their lost weight⁵, and the tirzepatide withdrawal trial showed the same pattern⁶. Continued treatment, by contrast, sustains the loss over years⁷. So the honest cash-pay math is not "what does one month cost" but "what does twelve months cost, from a provider I can actually stay with." A $99 teaser you abandon by spring buys you regain; a slightly higher flat price you can sustain for a year buys you the result. That is exactly what the Cost-Efficiency Index is built to measure.

How to pay the least without gambling on quality

Four moves, in order. First, decide molecule by value, not hype — tirzepatide leads on average weight loss but semaglutide is usually cheaper, and our semaglutide vs tirzepatide value guide helps you weigh the trade. Second, get the manufacturer self-pay price as your FDA-approved benchmark, then see whether a verified telehealth or compounded route beats it enough to matter. Third, compute the true annual cost for every finalist — month-one plus eleven maintenance months plus fees — not the intro sticker. Fourth, favor a flat-price, transparently-run provider like CoreAge Rx so month twelve costs the same as month one. Do those four and the "cheapest" option on the landing page is frequently not the cheapest once the year is priced honestly.

What's coming: an oral cash-pay option

One more shift worth budgeting for. A once-daily oral semaglutide at a 50 mg weight-management dose produced meaningful weight loss in its phase 3 trial³, and an oral GLP-1 that does not require injection or cold-chain handling could reshape self-pay pricing again once widely available. GLP-1s have also shown cardiovascular benefit in people with obesity and established heart disease⁴, and tirzepatide's edge over a semaglutide comparator in a head-to-head diabetes trial⁸ is part of why the efficacy-versus-price trade is worth doing deliberately. For now, price your own year across all three routes, and rank on the number you will really pay.